류마티스 질환의 코호트 연구 = Observational Cohort Studies in Rheumatic Diseases

다국어 초록 (Multilingual Abstract)

Rheumatic diseases are diverse groups characterized by a variety of clinical manifestations and diseasecourses in each patient. The best way to understand the course and prognosis of these patients is through observational cohort studies. The cohort studies also provide an opportunity to describe diseases outcomes including therapeutic responses and evaluate the effectiveness and safety of new therapy. It helps to understand disease pathogenesis and provide insight into the mechanisms of disease progression. The strengths of a cohort study are that it has a large number of patients over a long period of time. The patients in cohorts should be representative of the patients with diseases. Thoughtful study design and planning before establishment of cohorts will lead successful follow-up and increase data quality. The observation process must be clearly defined and followed according to the standard protocols.We reviewed numerous cohorts in rheumatic diseases and suggested the points to be considered for cohorts establishments. (Korean J Med 2014;87:548-556)

참고문헌 (Reference)

1 김담, "한국인 루푸스 임상연구의 현재와 미래" 대한류마티스학회 21 (21): 54-63, 2014

2 Iannaccone CK, "Using genetic and clinical data to understand response to disease-modifying anti- rheumatic drug therapy: data from the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study" 50 : 40-46, 2011

3 Gonzalez LA1, "Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi- ethnic lupus cohort" 18 : 822-830, 2009

4 Goldacre M, "The role of cohort studies in medical research" 10 : 5-11, 2001

5 Doll R, "The mortality of doctors in relation to their smoking habits; a preliminary report" 1 : 1451-1455, 1954

6 Isenberg DA, "The Systemic Lupus International Collaborating Clinics (SLICC) group - it was 20 years ago today" 20 : 1426-1432, 2011

7 Pons-Estel BA, "The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics" 83 : 1-17, 2004

8 Cervera R, "The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe" 18 : 869-874, 2009

9 Kremer J, "The CORRONA database" 64 (64): iv37-41, 2005

10 Askling J, "Swedish registers to examine drug safety and clinical issues in RA" 65 : 707-712, 2006

11 Gallinaro AL, "Spondyloarthritis: analysis of a Brazilian series compared with a large Ibero-America registry (RESPONDIA group)" 50 : 581-589, 2010

12 Mercer LK, "Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis" 2014

13 Desai SP, "Rheumatoid arthritis quality measures and radiographic progression" 44 : 9-13, 2014

14 Spoorenberg A, "Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis" 26 : 980-984, 1999

15 Ward MM, "Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease" 65 : 257-265, 2013

16 Pons-Estel GJ, "Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort" 48 : 817-822, 2009

17 Maurer B, "Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database" 2014

18 Yamanaka H, "Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice" 16 : 75-76, 2006

19 Almodovar R, "Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER)" 29 : 822-827, 2011

20 Oomatia A, "Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period" 66 : 1000-1009, 2014

21 Gladman DD, "Longitudinal cohort studies" 72 : 30-32, 2005

22 Curtis JR, "Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research" 2014

23 Cervera R, "Lessons from the "Euro-Lupus Cohort" 153 : 530-536, 2002

24 Sung YK, "Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea" 41 : 745-751, 2012

25 Komano Y, "Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Long term Safety" 38 : 1258-1264, 2011

26 Yamanaka H, "Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan" 17 : 283-289, 2007

27 Cui J, "Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis" 9 : e1003394-, 2013

28 Lie E, "First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register" 73 : 1905-1906, 2014

29 Dawber TR, "Epidemiological approaches to heart disease: the Framingham Study" 41 : 279-281, 1951

30 Lui NL, "Effect of pregnancy on ankylosing spondylitis: a case?control study" 38 : 2442-2444, 2011

31 Dixon WG, "EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology" 69 : 1596-1602, 2010

32 Sakai R, "Drug retention rates and relevant risk factors for drug dis continuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules" 71 : 1820-1826, 2012

33 Sherrer YS, "Disability in rheumatoid arthritis: comparison of prognostic factors across three populations" 14 : 705-709, 1987

34 Petri M1, "Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study" 34 : 937-944, 1991

35 Silman A, "British Society for Rheumatology Biologics Register" 62 : ii28-ii29, 2003

36 Lee W, "Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort" 66 : 633-638, 2007

37 Arkema EV, "Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments" 2014

38 Shinjo SK, "Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort" 62 : 855-862, 2010

39 Reveille JD, "A registry of ankylosing spondylitis registries and prospects for global interfacing" 25 : 468-476, 2013

40 Kvien TK, "A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases" 23 (23): S188-S194, 2005